Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI1191 CD8 PET imaging substudy in advanced solid tumors
NL-OMON52188Phase 1Withdrawn
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 1, open-label trial of MEDI1191, durvalumab and zirconium-89 crefmirlimab berdoxam in advanced nonhematological malignancy, melanoma and squamous cell carcinoma (SCC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Change in CD8 PET uptake in tumor and normal tissues, Correlation of CD8 PET uptake with CD8 tumor-infiltrating lymphocytes and 2 more. Planned start Nov 2021; status: withdrawn.
02
Drugs
MEDI1191durvalumabzirconium-89 crefmirlimab berdoxam
03
Conditions
advanced nonhematological malignancymelanomasquamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NL-OMON52188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52188.